tbuckley/cabot-search huggingface dataset:
Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial
Authors: Tait D. Shanafelt, Victoria Wang, Neil E. Kay, Curtis A. Hanson, Susan M. O'Brien, Jacqueline C. Barrientos, Diane F Jelinek, Esteban Braggio, Jose F. Leis, Cong Christina Zhang, Steven Coutre, Paul M. Barr, Amanda F Cashen, Anthony R. Mato, Avina Singh, Michael P. Mullane, Richard F. Little, Harry P. Erba, Richard M. Stone, Mark Litzow, Martin S. Tallman
Journal: Blood (2019)
CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial
Authors: Mingci Cai, Shu Cheng, Wang Xin, Jianda Hu, Yongping Song, Zixun Yan, Yujie Jiang, Xiaosheng Fang, Xiaoyun Zheng, Lihua Dong, Mengmeng Ji, Li Wang, Pengpeng Xu, Weili Zhao
Journal: Blood (2019)
Circulating miR-652-3p as a biomarker of drug resistance in metastatic colorectal cancer patients
Authors: S. Hedayat, A. Lampis, G. Vlachogiannis, K. Khan, D. Cunningham, S. Marchetti, M. Fassan, R. Begum, M. Schirripa, F. Loupakis, N. Valeri
Journal: Annals of Oncology (2019)
Preterm births: US panel recommends withdrawal of prevention drug in controversial vote
Authors: Elisabeth Mahase
Journal: BMJ (2019)

An independent advisory panel to the US Food and Drug Administration has recommended that approval should be removed for Makena (hydroxyprogesterone caproate), a drug used in the US to prevent preterm birth, because of a lack of evidence that it works.

In a meeting on 29 October the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee voted by nine to seven to withdraw approval for the drug. But the American College of Obstetricians and Gynecologists has warned that removing the drug from the market could be a mistake, and its manufacturer has claimed that five of the six obstetricians on the committee voted to keep Makena on the market.

The FDA is not bound by the committee’s decision and will conduct its own review of the committee’s feedback before making a final decision. However, the agency typically follows …
Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss
Authors: Xiaochuan Yang, Amber C. King, Charlene C. Kabel, Christopher J. Forlenza, Jae H. Park, Mark B. Geyer
Journal: Blood (2019)
EPID-02. HEIGHT AND THE RISK OF MENINGIOMA
Authors: Shlomit Yust-Katz, Alexandra Amiel, Ramiz Abu Shkara, Tali Siegal, Gilad Twig
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Meningiomas are the most common primary central nervous system tumors. Risk factors for meningiomas including obesity, height, history of allergy/atopy or autoimmune diseases, have been previously assessed with conflicting results. We reviewed a large cohort of Israeli adolescents in order to assess potential risk factors for the development of meningiomas. METHODS This study analyzed a cohort of 2,035,915 Jewish men and women who underwent obligatory physical examination when aged 16 to 19 years, from 1967 to 2011. Meningioma incidence was identified by linkage to the national cancer registry. Cox proportional hazard models were used to estimate the hazard ratios for meningioma according to sex, body mass index (BMI), height, history of allergic and autoimmune disease. RESULTS Linkage of the adolescent military database with the Israeli cancer registry identified 480 cases (152 males and 328 females) of meningioma during a follow up of 40,304,078-person years. The median age at diagnosis of meningioma was 42.1 ± 9.4 (range 17.4–62.6). On univariate analysis, only female gender (p&lt; 0.01) and height (p&lt; 0.01) were associated with risk for meningioma in the total study population. When stratified by gender, height remained a significant risk factor only in men. Spline analysis in the men group showed the minimum risk at a height of 1.62 meters and a statistically significant increase in the risk for meningioma at heights taller than 1.85 meters. BMI, past medical history including asthma, diabetes, and atopic and autoimmune diseases, were not associated with meningioma risk. CONCLUSION in this large population study, we found that sex and taller height in adolescent males was associated with an increased risk of adult meningioma.
TMOD-29. A MOUSE MODEL OF FGFR3-TACC3 UNCOVERS MECHANISMS OF GLIOMAGENESIS AND MAINTENANCE
Authors: Tala Fnu, Peiguo Shi, Jing Zhang, Antonio Iavarone, Anna Lasorella
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma harboring Fibroblast Growth Factor Receptor 3 (FGFR3)-Transforming Acidic Coiled-Coil containing 3 (TACC-3) (FGFR3-TACC3) fusion is a distinct molecular subclass of tumors that can be targeted by FGFR kinase inhibitors. We generated a knock-in mouse in which the expression of FGFR3-TACC3 is doxycycline inducible and reversible. The tetO-FGFR3-TACC3-IRES-GFP cassette was placed into the Rosa26 locus and the FGFR3-TACC3 knock-in strain was intercrossed with GFAP-rtTA*M2 mice to trigger expression of the tetracycline transactivator (and the fusion gene) from the GFAP promoter. To recapitulate the genetic lesions that are more frequently associated with FGFR3-TACC3 in human glioblastoma, we also intercrossed the tetO-FGFR3-TACC3-IRES-GFP;GFAP-rtTA*M2 mice with TP53+/-or Ink4A+/-mouse strains. Both strains developed aggressive and infiltrating gliomas within 90 days after induction of FGFR3-TACC3 by doxycycline containing diet. Tumors occurred with a prevalence of ~50% and were found almost exclusively at two brain locations: the lateral septum and the neuro-epithelium adjacent to the fimbria of the hippocampus, thus recapitulating the restricted expression of endogenous FGFR3 in the ventral telencephalon and ganglionic eminence during development. The FGFR3-TACC3-positive glioma resembled human glioblastoma as they exhibited marked invasiveness and vascularization, elevated proliferative index and positivity for Nestin and GFAP. Rapid tumor progression caused appearance of neurological symptoms and death within few weeks. Doxycycline withdrawal from the diet of mice diagnosed with brain tumors by MRI resulted in rapid loss of FGFR3-TACC3 from glioma cells, marked inhibition of tumor growth with essentially complete glioma regression in some cases and recovery of general and neurological clinical symptoms. Our findings validate FGFR3-TACC3 as powerful oncogene that drives development of high-grade glioma from distinct areas of the brain. They also provide an accurate pre-clinical model in which glioma maintenance requires continuous expression of the fusion gene, thus supporting therapeutic targeting of the fusion protein in patients with FGFR3-TACC3-positive glioblastoma.
Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials
Authors: Amar U. Kishan, Fang-I Chu, Christopher R. King, Wendy Seiferheld, Daniel E. Spratt, Phuoc Tran, Xiaoyan Wang, Stephanie E. Pugh, Kiri A. Sandler, Michel Bolla, Philippe Maingon, Theo De Reijke, Nicholas G. Nickols, Matthew Rettig, Alexandra Drakaki, Sandy T. Liu, Robert E. Reiter, Albert J. Chang, Felix Y. Feng, Dipti Sajed, Paul L. Nguyen, Patrick A. Kupelian, Michael L. Steinberg, Paul C. Boutros, David Elashoff, Laurence Collette, Howard M. Sandler
Journal: European Urology (2019)
The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy
Authors: Lazaros J. Lekakis, Craig H. Moskowitz
Journal: HemaSphere (2019)

For many years now and based on the results of the PARMA trial, relapsed Diffuse Large B-cell Lymphoma (DLBCL) is treated with salvage combination cytotoxic chemotherapy (most often platinum-based) followed by high dose myeloablative chemotherapy and autologous stem cell transplantation (auto-HCT). This approach has resulted in long-term disease free survival in about half of the patients. With the incorporation of rituximab in the upfront treatment (RCHOP), more patients with DLBCL are cured but there has been a signal of inferior outcomes with auto-HCT if DLBCL relapses. Nevertheless, a careful review of the literature still shows very good outcomes with auto-HCT for DLBCL with complete remission to salvage chemotherapy. For those who do not respond well to classic salvage other approaches are reviewed here including chimeric antigen receptor (CAR) T-cell therapy and treatment with antibody-drug conjugates (ADCs) as well as bispecific T-cell engagers (BiTEs). The outcome of auto-HCT after successful treatment with ADCs or BITEs is unknown. It is also unknown if CAR-T cell therapy should be reserved for those who have failed 2 lines of chemotherapy or it should be moved earlier. Finally, we review here the effects of Myc and bcl2 amplifications or translocations to the outcome of the auto-HCT. Some attempts to improve the salvage or conditioning regimens are mentioned. We also discuss the role of allogeneic stem cell transplantation (allo-HCT) in the paradigm of treatment for relapsed DLBCL.
Comprehensive Transcriptome Profiling of Cryptic <i>CBFA2T3–GLIS2</i> Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study
Authors: Jenny L. Smith, Rhonda E. Ries, Tiffany Hylkema, Todd A. Alonzo, Robert B. Gerbing, Marianne T. Santaguida, Lisa Eidenschink Brodersen, Laura Pardo, Carrie L. Cummings, Keith R. Loeb, Quy Le, Suzan Imren, Amanda R. Leonti, Alan S. Gamis, Richard Aplenc, E. Anders Kolb, Jason E. Farrar, Timothy J. Triche, Cu Nguyen, Daoud Meerzaman, Michael R. Loken, Vivian G. Oehler, Hamid Bolouri, Soheil Meshinchi
Journal: Clinical Cancer Research (2019)

A cryptic inv(16)(p13.3q24.3) encoding the
NCOG-11. NEUROPSYCHOLOGICAL OUTCOMES FOLLOWING AWAKE CRANIOTOMY FOR LOW GRADE GLIOMA
Authors: Daniel O’Hara, Amy Miller, John Goodden, Christopher Graham, Hayley Kitchingman, Ryan Mathew, Oliver Richards, Paul Chumas
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Awake craniotomy is an established treatment for tumours in eloquent brain regions. It aims to achieve maximal resection without significant neurological and functional morbidity. There is an emerging evidence base about the neuropsychological outcomes following awake craniotomy for low grade gliomas (LGGs) with inconsistent findings potentially reflective of methodological confounders such as the inclusion of mixed tumour types and the use of varied neurocognitive measures and timescales for repeat testing. We describe detailed neuropsychological outcomes for a cohort of patients following awake craniotomy for LGGs. METHOD Data were collected from patients undergoing first-time awake resection of presumed LGGs at Leeds Teaching Hospitals, UK between 2010 and 2018. Patients were included if they consented to and completed the full battery of pre- and postoperative neuropsychological testing. Neuropsychometric testing involved assessment of general intellectual functioning, language, memory, executive functioning, perception, processing speed and mood. Data were analysed using paired-samples t-test or Wilcoxon signed-rank test with Bonferroni correction for multiple statistical comparisons. RESULTS Twenty-two patients undergoing awake craniotomy for presumed supratentorial LGG (13 left hemisphere, 9 right hemisphere; mean age 35 years) met the above inclusion criteria. Tumour location was heterogenous (11 insular, 9 frontal, 1 temporal, 1 parietal). Histopathology confirmed WHO Grade II diffuse astrocytoma (n=11), WHO Grade II oligodendroglioma (n=10) and WHO Grade III anaplastic oligodendroglioma (n=1). No statistical differences in neurocognitive test scores were found pre- and post-neurosurgery (mean follow-up was 61 weeks). Other outcomes including extent of resection and reliable change statistics for neurocognitive tests and measures of mood were also analysed. CONCLUSION No significant change in neurocognitive functioning was found in patients following recovery from awake craniotomy for LGG. Our findings suggest that awake craniotomy is a safe treatment for LGG and that neuropsychological input is an important part of the treatment pathway for patients with LGG.
Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL
Authors: Shanye Yin, Salma Parvin, Elisa Ten Hacken, Rebecca Valentin, Heather Joyal, Laura Z. Rassenti, Emanuela M. Ghia, Thomas J. Kipps, Donna S Neuberg, Lili Wang, Matthew S. Davids, Ruben D. Carrasco, Anthony G. Letai, Catherine J. Wu
Journal: Blood (2019)
ABL Kinase Domain Mutation in Chronic Myeloid Leukemia - Compliance to Imatinib Matters
Authors: Jayachandran PK, Trivadi S Ganesan, Nikita Mehra, Krishnarathinam Kannan, Manikandan Dhanushkodi, Venkatraman Radhakrishnan, Arun Kumar Rajan, Joshi Archit Girishchandra, Gangothri Selvarajan, Parathan Karunakaran, Tenali Gnana Sagar
Journal: Blood (2019)
SCIDOT-51. OVERPOWERING MULTIPLE INHIBITORY IMMUNE CHECKPOINTS WITH A SINGLE PEPTIDE INHIBITOR ENHANCED SURVIVAL IN A SPONTANEOUS HIGH-GRADE GLIOMA CANINE PILOT-TRIAL
Authors: Michael Olin, Christopher Moertel, G Elisabeth Pluhar
Journal: Neuro-Oncology (2019)

Abstract Given the modest effects current immune checkpoint-inhibitors have on patients with CNS tumors, we focused our studies on the novel CD200 immune checkpoint. The CD200 checkpoint suppresses the immune system through binding of the inhibitory CD200 protein to the inhibitory receptor (CD200R1) expressed on immune cells. In addition to CD200R1, the CD200 checkpoint includes activation receptors (CD200AR), which we are targeting with a peptide ligand (CD200AR-L) to reverse the inhibitory effects of the CD200 protein. We showed that spontaneous high-grade glioma dogs receiving a canine specific CD200AR-L in combination with autologous tumor lysate vaccine had an increased median overall survival of 9 months, compared to 6.3 months with lysate alone, resulting in an overall 36-month survival of 21%. However, we have a 45% event-free (progression-free) group of dogs that died of non-tumor related deaths with an extended median survival of 18 months. Six dogs remain on trial, 87% of the dogs receiving tumor lysate only died of tumor recurrence within 6 months. Serum chemistry profiles and physical examinations showed that the peptide did not induce any systemic toxicity. To determine how we obtained these unprecedented results, we focused on the mechanism of CD200AR-L/CD200AR binding. We discovered DAP10/12 signaling pathways and CD200ARs are upregulated, while the inhibitory CD200R1 is downregulated. We discovered the molecular connection between CD200, PD-1 and CTLA4. We demonstrated that our murine and human CD200AR-L downregulates the inhibitory PD-1 and PD-L1 and inhibits the upregulation of CTLA4. Therefore, we attribute the success of CD200AR-L to the ability to concurrently modulate multiple immune checkpoints. We have now developed human GMP grade CD200AR-L peptides to develop an immunotherapy approach for patients with CNS tumors; we will conduct a Phase I trial utilizing the peptide ligand concomitantly with an allogeneic GBM6-AD cell line as a tumor vaccine and the adjuvant imiquimod.
QOLP-34. DOSE FREQUENCY MODIFICATION OF TRAMETINIB TO MITIGATE SEVERE RASH AND IMPROVE QUALITY OF LIFE IN PEDIATRIC LOW-GRADE GLIOMA PATIENTS
Authors: Bridget Archambault, Daniel Landi, Kristin Schroeder
Journal: Neuro-Oncology (2019)

Abstract Circumscribed low-grade glioma is generally driven by MAP kinase pathway activation, and this discovery motivates use of the non-competitive MEK 1/2 inhibitor trametinib for children and adults with progressive disease. However, rash is a common dose-limiting toxicity with trametinib. Accordingly, we evaluated intermittent, 3-days-on, 1-day-off dosing in an effort to reduce the incidence and severity of rash. Seven patients with MAP-kinase activated low grade glioma were treated with trametinib (6 pilocytic astrocytoma (PA), one desmoplastic infantile ganglioglioma with V600E). Patients initiated treatment at 0.025mg/kg/day up to the maximum adult dosing of 2mg. Three teenage patients with PA were treated with the maximum daily adult dose of 2mg. All three developed a painful, grade 3 acneiform rash within 3 weeks, requiring trametinib hold and treated with topical cleansers and oral antibiotics. One patient discontinued treatment, and two restarted trametinib at a reduced dose (1.5mg) administered 3-days-on and 1-day-off. With this modified dosing, patients experienced no more than grade 1 rash. Two younger patients initiated trametinib with daily dosing, and both developed grade 1 eczematous rash within 3 weeks, progressing to grade 2 in one patient. The rash resolved without recurrence after dose frequency modification to 3-days-on, 1-day-off at the same overall dose. Two younger patients initiated trametinib with 3-days-on, 1-day-off dosing and have not developed a rash. All of the younger patients are currently continuing on therapy with no progression to date. However, both teenage patients developed progressive disease by 11 months into therapy. In conclusion, acneiform rash appears to preferentially impact teenage or young adult patients but can be mitigated with modified dose frequency 3 days on, 1 day off. However, continued assessment is needed to evaluate the effect of dosing frequency modification on treatment response.
MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients
Authors: Kirill A. Lyapichev, L. Jeffrey Medeiros, Shaoying Li, C. Cameron Yin, Guilin Tang, M. James You, Sergej Konoplev, Swaminathan P. Iyer, Carlos E. Bueso-Ramos, Roberto N. Miranda, Jie Xu
Journal: Blood (2019)
Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An International Study of 108 Patients
Authors: Fredrik Ellin, Knut B. Smeland, Tove Wästerlid, Jacob H. Christensen, Judit Jørgensen, Pär L. Josefsson, Harald Holte, Yngvild Nuvin Blaker, Jacob H. Grauslund, Jon Bjoern, Daniel Molin, Ingemar Lagerlöf, Karin Ekstrom Ekstroem Smedby, Katherine Colvin, Gita Thanarajasingam, Matthew J Maurer, Thomas M. Habermann, Kevin Song, Katie Yuan Zhu, Alina S Gerrie, Chan Y. Cheah, Tarec Christoffer C. El-Galaly, Lasse H. Jakobsen
Journal: Blood (2019)
Biomarker Profile for Prediction of Patient Response to Smac Mimetic Monotherapy in Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia
Authors: Julia Zinngrebe, Ferdinand Schlichtig, Malcolm Meyer, Johann M. Kraus, Elena Boldrin, Hans A. Kestler, Lüder Hinrich Meyer, Pamela Fischer-Posovszky, Klaus-Michael Debatin
Journal: Blood (2019)
Phase II trial of everolimus in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Authors: Prakash Varadarajan, Athanasios Panayotis Kotsakis, Daniel Martin, Jorge Silvio Gutkind, Michael K. Gibson, Athanassios Argiris
Journal: Journal of Clinical Oncology (2012)

5541 Background: The PI3K/Akt/mTOR pathway plays an important role in SCCHN pathogenesis and resistance to treatment. We conducted a phase II study of everolimus, an oral inhibitor of mTOR, in patients with refractory SCCHN. Methods: Patients with recurrent or metastatic SCCHN treated with at least 1 prior regimen, performance status (PS) 0-2, and adequate organ function, received everolimus 10 mg once daily orally. The primary endpoint was the disease control rate (DCR) defined as the proportion of patients with a complete response, a partial response, or stable disease. A two-stage design was followed. Cytokines were measured in plasma and serum at baseline and post treatment. Results: 9 patients were enrolled. Median age 63 years (range 51 - 82), Male/Female, 6/3, performance status 0/1/2, 2/5/1. Primary site: oropharynx (2), oral cavity (4), larynx (1), others (2). Median number of palliative therapies in the recurrent/metastatic setting prior to study was 1 (range 1- 4). Median number of cycles of everolimus delivered was 1 (range 1-5). No objective responses were seen. One patient had stable disease that lasted 6 months but all other patients had progression as best response. DCR was 11%. Median progression-free survival was 40 days. Four patients have died due to disease progression. Grade 3 adverse events were infrequent: pain (2 patients), anemia (2 patients), and 1 patient each with pruritus, hypertransaminasemia, hyponatremia, lymphopenia, and fatigue. No Grade 4 toxicities were reported. Biomarker analysis in 2 patients with available post treatment samples showed reduced plasma levels of VEGF-A, Gro-α, and IL-17, after everolimus treatment, but no reduction was observed in the plasma levels of IL-6 and IL-8, two cytokines often associated with SCCHN disease progression. Conclusions: Everolimus as monotherapy was well tolerated but did not have sufficient activity in this setting. This phase II study did not meet the predefined primary endpoint in the first stage of accrual.
PATH-34. CLINICOPATHOLOGIC, MOLECULAR AND IMMUNOLOGICAL CHARACTERIZATION OF DIFFUSE MIDLINE GLIOMAS: IS THERE A PROGNOSTIC SIGNIFICANCE?
Authors: Niveditha Manjunath, Prerna Jha, Amol Raheja, Vaishali Suri, Ashish Suri, Ajay Garg, Kavneet Kaur, Chitra Sarkar
Journal: Neuro-Oncology (2019)

Abstract H3K27M Diffuse Midline Gliomas (DMGs) are amongst the most fatal cancers, considered WHO grade IV irrespective of the histological features. Treatment modalities have been ineffective in prolonging survival. The aim was to determine the clinico-pathologic, molecular and immunological characteristics of DMGs in children and adults. Genetic (H3K27M, ATRX, IDH1, p53) and immune (CD3,CD8 and PD-L1) profile of 126 DMGs identified over 10 years was studied with immunohistochemistry (IHC). Sanger sequencing performed for IDH1 and H3K27M mutation. Clinico-radiologic characteristics were reviewed and survival analysis performed. Of the 126 DMGs, 49.2% H3K27M mutant and 50.8% wildtype cases (mean age 21.27 years vs. 36.23 years). 75.68% of pediatric whereas 38.20% of adults were H3K27M mutant. Brainstem (46%) was commonest site in H3K27M mutant pediatric cases while majority of adults (62%) were thalamic. H3K27M was mutually exclusive with IDH mutation in 92.5% cases, whereas p53, ATRX mutation was 56.4% and 30.6% respectively. IHC showed 95% concordance with Sanger sequencing for H3K27M mutation. PD-L1 expression was greater in elderly (&gt;50 years), than young adults and pediatric cases (p=0.002). CD8 expression was greater in adult then pediatric cases (p=0.0001). Overall survival (OS) was not statistically significant in mutant versus wildtype cases in children (p=0.45) as well as adults (p=0.65). Tumor location showed no correlation with OS. Tumor resection independently or on correlation with H3K27M did not influence OS (p=0.505 and p=0.470). Adjuvant therapy impacted survival significantly in adults (p=0.0009) than in pediatric patients (p=0.0669) The study highlights the differences in frequency and location of pediatric and adult H3K27M mutant DMGs. Dismal prognosis in both age groups of H3K27M mutant and wild type DMGs. IHC for H3K27M mutation is an excellent substitute to Sanger sequencing. Our analysis emphasises the role of molecular characterisation for the development of effective therapeutic strategies, for different DMG subgroups.
Generation of a New Prognostic Index for Chronic Myelomonocytic Leukemia (CMML) Based on Peripheral Blood Assessment
Authors: David Roman, Leonor Arenillas, Ivonne Parraga, Lourdes Florensa, Sara Montesdeoca, Marta Salido, Puiggros Anna, Blanca Espinet, Lluís Colomo, Marcio Andrade, Brayan Merchan, Ana Ferrer, Xavier Calvo
Journal: Blood (2019)
Combination of Interferon α, Delivered By Engineered Mesenchymal Stromal Cells, and Cytarabine Limits the Development of Acute Myeloid Leukemia, Potentially Targeting Leukemic Stem Cells
Authors: Desbourdes M. Laura, Suheyla Hasgur, Adam J Guess, Minjun Yu, Satoru Otsuru, Edwin M. Horwitz
Journal: Blood (2019)